本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for Mainland China Extension of Exclusive License and Distribution Agreement to include seven additional countries across East and South East Asia with cumulated population > 630 million SHANGHAI, Sept. 23, 2024 /PRNewswire/ -- Nuance Pharma (the "Company") today announced that it has agreed with Altamira Medica Ltd., an associate company of Altamira Therapeutics Ltd. (Nasdaq:CYTO), to extend the territory covered by the exclusive license and distribution agreement for Bentrio® nasal spray by several countries across South East and East Asia. Under the amended agreement, Nuance's territory will expand from China (Mainland, Hong Kong, Macau) and South Korea to also include Singapore, Malaysia, Thailand, Philippines, Indonesia, Vietnam and Taiwan, with a combined population of greater than 630 million people. Nuance has been marketing Bentrio in Hong Kong since late 2022 and recently submitted the request for marketing approval for Mainland China. "We are excited to reinforce and expand our successful collaboration with Altamira on Bentrio," stated Mark Lotter, founder and CEO of Nuance Pharma. "Bentrio offers some unique features such as immediate onset and long duration of protection against airborne particles, strong efficacy and good tolerability thanks to its drug-free and preservative-free formulation. They resonate well with medical professionals and consumers, and we look forward to rolling out the product in additional countries and marketing it through our large sales force and growing network of partners." "We are very satisfied with the collaboration with our partner Nuance who has shown great dedication and launched Bentrio successfully in Hong Kong," commented Thomas Meyer, Altamira Medica's Chairman and CEO. "Together with Nuance we look forward to making Bentrio available in further countries, first in the existing license territory and subsequently also in the newly added countries to provide relief to the growing number of allergic rhinitis patients in East and South East Asia." About Bentrio Bentrio is a drug-free nasal spray for personal protection against airborne allergens and, where approved, against airborne viruses. Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of airborne particles with cells; in addition, the composition serves to bind such particles and help with their discharge. The efficacy and safety of Bentrio has been demonstrated in a total of four clinical trials, of which the largest one ("NASAR" study) enrolled 100 patients suffering from seasonal allergic rhinitis. In NASAR, participants self-administered either Bentrio or saline nasal spray for two weeks 3 times per day. The study showed a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline (p = 0.013), as well as a statistically highly significant improvement in health-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire, p < 0.001) and superior global ratings of efficacy by patients and investigators alike (p < 0.001). In addition, Bentrio showed good safety and tolerability, similar to saline controls, and fewer Bentrio treated patients used relief medication and more of them enjoyed symptom-free days compared to saline treatment. For more information, visit: www.bentrio.com. About Nuance Pharma Nuance Pharma is an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset portfolio. Focusing on specialty care, Nuance has established a differentiated combination of commercialized assets and innovative pipeline across respiratory, pain management, emergency care and iron deficiency anemia. With the mission to address critical unmet medical needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a global leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia as a region. For more information, please visit www.nuancepharma.com. About Altamira Therapeutics Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/. Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
SHANGHAI, Sept. 23, 2024 /PRNewswire/ -- At HUAWEI CONNECT 2024, Huawei teamed up with partners to launch the Medical Technology Digitalization 2.0 Solution at the healthcare session named Enhancing Inclusivity to Amplify Healthcare Intelligence. This solution implements AI-assisted diagnosis and intelligent quality control, facilitating precision healthcare as well as hierarchical diagnosis and treatment. Huawei and partners launch the Medical Technology Digitalization 2.0 Solution Participants of the launch ceremony were: Sun Pengfei, Vice President of Huawei Global Public Sector; Hou Yu, Founder and CEO of MED Imaging AI; Zhang Yu, General Manager of Wanxiang Medical Technology Co., Ltd.; Sun Fenglei, Product Strategy Director of Beijing DeepWise Technology Co., Ltd.; and Liu Zheng, Business Development Director of KFBIO. AI Enablement, Achieving Precise and Consistent Diagnosis and Treatment Medical image data accounts for 80% of clinical data. AI is used to fully explore the value of such data, which is critical to clinical diagnosis, decision-making, and disease prevention. Incorporating AI, computing, storage, and network, Huawei's Medical Technology Digitalization 2.0 Solution works with the innovative applications of industry partners to implement AI-based quality control and diagnosis, significantly improving the quality and efficiency of healthcare services. So far, this solution has been implemented in projects like the Fourth People's Hospital of Shenyang. In medical imaging, this solution can intelligently identify and score the quality of images. The accuracy of AI quality control reaches 98%, boosting image quality. In addition, the solution supports the intelligent segmentation, detection, and quantitative analysis of image data, and can automatically complete AI analysis and auxiliary diagnosis, effectively reduces the missed diagnosis rate. The diagnosis time is shortened by 40%, significantly increasing the diagnosis and treatment efficiency. For ultrasounds, this solution uses digital and intelligent imaging devices running on the OpenHarmony. With the AI device-edge synergy architecture deployed in the center, AI and low latency video transmission help achieve one-stop, real-time AI-assisted diagnosis and centralized quality control regionwide. Ultrasound quality control can now realize full coverage instead of just conducting spot checks. The end-to-end delay of all-domain AI-assisted diagnosis is less than 150 ms, which facilitates continuous improvement of ultrasound diagnosis quality and efficiency across the region. All-Scenario Innovation, Accelerating Healthcare Intelligence Li Junfeng, Vice President of Huawei and President of the Global Public Sector, said that the next few years hold important opportunities for digital and intelligent technologies to propel the high-quality development of healthcare. Huawei focuses on root technologies and continuously innovates and optimize scenario-specific solutions for the healthcare industry, such as the Smart Ward, Smart Hospital Campus, and Telemedicine. To date, Huawei has served over 5000 healthcare institutions in more than 110 countries and regions.
YANGZHOU, China, Sept. 21, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today reported its unaudited financial results for the six months ended June 30, 2024. All amounts below are in U.S. dollars. First Half 2024 Unaudited Financial Metrics: Revenues was approximately $45.3 million for the six months ended June 30, 2024. Gross profit was approximately $15.2 million for the six months ended June 30, 2024. Gross margin was approximately 33.5% in the six months ended June 30, 2024. Income from operations was approximately $5.9 million for the six months ended June 30, 2024. Net income was approximately $4.7 million for the six months ended June 30, 2024. Mr. Yongjun Liu, Chairman of the Company, commented, "In the first half of 2024, we have been actively transitioning toward the high-end medical device industry, which is reflected in our financial results. Our total revenue for the first half of 2024 was $45.3 million, with a gross profit of $15.2 million and a gross margin of 33.5%. Given the overall economic slowdown during this period, we are pleased with these results. While these headwinds have impacted our short-term profit, they underscore the need to strengthen our operational resilience and focus on long-term sustainability. Currently, we are actively optimizing our product mix, increasing our focus on high-margin, high-quality consumables, and expanding our premium medical products portfolio. At the same time, we are reinforcing our upstream and downstream supply chains with the goal of achieving greater efficiency. The integration of AI capabilities not only drives innovation and operational improvements within our company but also enhances the products we deliver to business partners, positioning us to offer advanced, intelligent solutions across the market. In particular, our Speed Fox warehouse management and logistics platform was launched in May, and we participated in the world's second-ever remote robotic lobectomy in July." "In addition, the construction of our integrated medical industrial park in Hainan is progressing well, and we expect it to further support our long-term growth objectives. We are confident this project, along with our other innovations and developments, will enhance our competitiveness and set a strong foundation for future financial performance." "In line with our confidence in the Company's long-term prospects, we have initiated a $3 million share repurchase plan, reflecting our belief in the underlying value of our business. This decision underscores our commitment to creating shareholder value while maintaining a disciplined approach to capital allocation. Despite the short-term hurdles, we believe we are well-positioned to navigate this period of uncertainty and build sustainable growth in the coming quarters." First Half 2024 Unaudited Financial Results: Revenues Revenues decreased slightly by approximately $2.9 million, or 5.9% to approximately $45.3 million for the six months ended June 30, 2024, from approximately $48.2 million in the same period of fiscal year 2023. The decrease in revenues was primarily driven by a decline in demand for customer orders, which we attributed to the stalling recovery of China's economy. Cost of revenues Cost of revenues primarily included the cost of materials, direct labor expenses, overhead, and other related incidental expenses that are directly attributable to the Company's principal operations. Cost of revenues decreased by approximately $0.9 million, or 2.8%, to approximately $30.2 million for the six months ended June 30, 2024, from approximately $31.0 million in the same period of fiscal year 2023. The decrease was generally in line with the decrease in revenue except for certain fixed costs such as lease expense and salary of administrative employees in our production department. Gross profit and margin Gross profit decreased by approximately $2.0 million, or 11.6%, to approximately $15.2 million for the six months ended June 30, 2024, from approximately $17.2 million in the same period of fiscal year 2023. Gross profit margin was 33.5% for the six months ended June 30, 2024, compared to 35.6% for the six months ended June 30, 2023. This decline was primarily due to certain fixed costs not decreasing proportionately with revenue, while other factors remained largely unchanged. Operating costs and expenses Our operating costs and expenses consist of selling expenses, general and administrative expenses, and research and development expenses. -Selling Selling expenses increased by approximately $40,000, or 1.2%, to approximately $3.2 million for the six months ended June 30, 2024, from approximately $3.2 million in the same period of 2023. The increase in selling expenses was mainly due to the market business development expenses increased. 1) Conference expenses increased by approximately $10,000, or approximately 2.4%, to $0.5 million for the six months ended June 30, 2024, from approximately $0.5 million for the six months ended June 30, 2023. Conference expenses are mainly related to the company's market expansion, business development, business negotiation, medical expo, and exhibition affairs. These expenditures helped the Company promote its products, develop markets and channels, strengthen customer communication, and establish long-term and stable cooperative relations. 2) Transportation expenses decreased by approximately $20,000, or approximately 1.9%, to $1.1 million for the six months ended June 30, 2024, from $1.1 million for the six months ended June 30, 2023. The reduction in business travel was due to a decline in demand for customer orders. 3) Salary and benefits expenses decreased by approximately $30,000 or approximately 5.0%, to approximately $0.7 million for the six months ended June 30, 2024 from approximately $0.7 million for the six months ended June 30, 2023. The decrease was due to a decrease in the salary and benefits of the sales team, which was in line with revenue decrease. 4) Business development expenses amounted to approximately $0.6 million and $0.5 million for the six months ended June 30, 2024 and 2023, respectively. 5) Auto expenses increased by approximately $20,000 for the six months ended June 30, 2024. Other expenses mainly consisted of certification fees, depreciation expenses, express fees, communication fees and loading fees. -General and administrative expenses General and administrative expenses increased by approximately $50,000, or 1.5%, to approximately $3.5 million for the six months ended June 30, 2024, from approximately $3.5 million in the same period of fiscal year 2023. The increase was primarily due to service expenses increasing by approximately $0.2 million from $0.7 million for the six months ended June 30, 2023 to $0.9 million for the six months ended June 30, 2024 due to an increase in investment consulting fees. - Research and development expenses Research and development expenses remained at $1.5 million for the six months ended June 30, 2024, as compared to the same period of fiscal year 2023. Income from operations Income from operations was approximately $5.9 million for the six months ended June 30, 2024. Net income Net income was approximately $4.7 million for the six months ended June 30, 2024, as a result of the factors described above. Recent developments On June 26, 2024, the board of directors (the "Board") of the Company approved and authorized the Company's proposal to adopt a share repurchase plan of up to $3 million of the Company's outstanding ordinary shares (the "Share Repurchase Plan"). Under the Share Repurchase Plan, Company management is authorized to purchase ordinary shares from time to time through open market purchases or privately negotiated transactions at prevailing prices as permitted by securities laws and other legal requirements, including Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, as well as the Company's insider trading policy, and subject to market conditions and other factors. About Meihua International Medical Technologies Co., Ltd. Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under Meihua's own brands and are also sourced and distributed from other manufacturers. The Company has received an international "CE" certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 800 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania. For more information, please visit www.meihuamed.com. Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua. Forward-Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's ability to achieve its goals and strategies, and its ability to fully execute on the planned agreement, the Company's future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, including under the section entitled "Risk Factors" in its annual report on Form 20-F, as well as on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For investor and media inquiries, please contact: IR DepartmentEmail: secretary@meihuamed.com Tel: +86-0514-89800199 ChristensenYang SongEmail: yang.song@christensencomms.com Tel: +86-010-59001548
Project ONE is an investment by INEOS in the Antwerp chemical sector for the construction of an ethane cracker. The investment amounts to over four billion euros, making it the largest investment in European chemistry in more than 20 years. INEOS Project ONE paves the way for renewal of the European chemical industry with state-of-the-art technology for sustainable production at the lowest environmental footprint that will reduce carbon emissions by approximately 2 million tons per year. AG&P Industrial, selected from among top 15 yards globally, to ship a total of 77 pre-assembled pipe rack modules and 58 pre-assembled support structures, weighing 10,443 MT for modules and 274 MT for support structures for INEOS Project ONE. AG&P Industrial's last shipment is expected sail by February 2025. Wood Group selected as the engineering, procurement, and construction management (EPCM) arm for INEOS Project ONE. MANILA, Philippines, Sept. 20, 2024 /PRNewswire/ -- AG&P Industrial (Atlantic, Gulf, & Pacific Company of Manila, Inc.), a leading diversified, full-asset lifecycle engineering, procurement, fabrication, construction, installation, and commissioning (EPFCIC) infrastructure development and operations and maintenance (O&M) company, has completed the fabrication and shipment of the first batch of Outside Battery Limit (OSBL) modules with a total weight of 1,432.47MT for its first-ever European contract with London-based INEOS, the fourth largest chemical company in the world. Fabricated in AG&P Industrial's state-of-the art fabrication yard in Batangas, Philippines, the modules were shipped to Port of Antwerp, Belgium, the second largest chemical site in the world. AG&P Industrial creates history by setting sail its first-ever module shipment to Europe The OSBL modules will support INEOS' Project ONE, a novel ethane cracker plant with a capacity of 1,450 kt of ethylene per year. Designed to be one of Europe's most efficient and sustainable chemical plants, Project ONE will provide ethylene, a key building block in chemistry, at the lowest carbon footprint making overall use of the best available techniques. Consumers of Project ONE's ethylene will cut carbon emissions by two million tons per year as compared to the available alternatives today – an equivalent of greenhouse gas emissions produced by 1.6 million gasoline-powered passenger vehicles driven for one year, or carbon dioxide emissions from 867,574 homes' energy use for one year[1]. AG&P's scope of work includes detail engineering, procurement, fabrication, and modularization of pre-assembled units and pipe racks to be made in state-of-the-art facility yard in Batangas. Project ONE will be completed with the Wood Group as the engineering, procurement, and construction management (EPCM) arm, with all three entities collaborating as one integrated team to deliver the critical project. "We are honored to be selected by INEOS for its flagship project and for the opportunity for AG&P Industrial to enter Europe for the very first time in our over a century of existence. AG&P Industrial was selected by INEOS from among top 15 yards globally, qualifying with necessary certifications and stringent European industry standards of construction. INEOS Project ONE represents AG&P Industrial's global prowess to serve Australia, Asia, US, and now, Europe, and affirms our world-class capabilities, qualifications, market-leading credentials, and proven track record. It also represents AG&P Industrial's commitment to contribute to lowering carbon emissions across the world," said Alex Gamboa, President and Managing Director of Global Business Development, AG&P Industrial. "Project ONE will provide renewal to the European chemical industry with state-of-the-art technology at the lowest environmental footprint. Specialized in building simple-to-complex process modules for the industrial sector with world-standard safety and quality record and powered by a diversified and highly experienced project delivery team, we found AG&P Industrial to be an ideal partner to support us in the build-out of our ethane cracker," said Jason Meers, Chief Financial Officer of INEOS Project ONE. AG&P Industrial has employed more than 2,100 for the project Batangas, Philippines, with all craftsmen trained and certified to European standards. The INEOS partnership supports AG&P's commitment to create livelihood and employment for local workers with a multiplier impact on the local economy of Batangas. [1] https://www.epa.gov/energy/greenhouse-gas-equivalencies-calculator About AG&P Industrial A subsidiary of the AG&P Group, AG&P Industrial, Manila is a leading diversified full-asset lifecycle EPFCIC (Engineering, Procurement, Fabrication, Construction, Installation and Commissioning), infrastructure development, and Operations & Maintenance (O&M) company with a legacy of executing award-winning marquee projects globally for LNG terminals, refineries, petrochemical plants, utilities, LNG liquefaction modules and other complex process units. It is also one of the largest Philippine industrial construction companies, operating a world-class manufacturing site in Batangas with deepwater access and 60,000MT of annual module assembly capacity. We build large segments of projects and complex process modules in a controlled environment with the highest standards of safety and quality. For more information, please visit https://industrial.agpglobal.com/. About INEOS Project ONE Project ONE is an investment by INEOS in the Antwerp chemical sector for the construction of an ethane cracker. The investment amounts to over four billion euros, making it the largest investment in European chemistry in more than 20 years. The advanced plant will produce ethylene, one of the most widely used basic chemicals worldwide and an essential building block for a variety of products, found in medical applications, textiles, computer and smartphone casings, household appliances, packaging to preserve food longer and cosmetics. It is also used in lightweight parts for cars and wind turbines, insulation materials for the construction industry or pipes for transporting drinking water. Project ONE will raise the standard for the chemical sector in Europe by deploying best available techniques. In particular, the investment will pioneer energy efficiency and have a carbon footprint less than half that of the 10% best steam crackers in Europe. The end of 2026 is targeted as the start of operation. The investment in Lillo will create 450 direct jobs and thousands of indirect jobs. At the peak of construction work, some 2,500 workers will be employed at the Antwerp site. More information at: https://project-one.ineos.com About INEOS INEOS is a global manufacturer operating in the petrochemical sector and manages 36 separate businesses. We operate 194 plants in 29 countries and employ 26,000 people worldwide. INEOS makes the raw materials and energy for everyday life. Our products make a vital contribution to society and are essential in applications ranging from preserving food to providing clean water; from building wind turbines, solar panels and other renewable technologies to building lighter and more fuel-efficient vehicles and aircraft; from medical equipment and pharmaceuticals to clothing and household appliances. In recent years, INEOS has diversified with the launch of INEOS Automotive and INEOS Hygienics. As part of its strategy to reduce greenhouse gas emissions, INEOS' businesses have introduced plans and actions needed to ensure they lead the transition to a net zero economy by 2050 at the latest. For more information, please visit https://www.ineos.com/
SHANGHAI, Sept. 19, 2024 /PRNewswire/ -- Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held in Shanghai from August 27 to 30, 2024, co-hosted by LeadLeo. Based on research and analysis of the global cognitive impairment digital therapy market, as well as studies and evaluations of relevant companies in the industry, Frost & Sullivan has granted BRAINAU the Global Cognitive Impairment Digital Therapy Innovation Award. Mr. Aroop Zutshi, the Global Managing Partner and Executive Board Member of Frost & Sullivan, and Professor Yu Wang, the Chairman of Chinese Foundation for Hepatitis Prevention and Control and the Director General of Chinese Center for Disease Control and Prevention presented this award to Dr. Xiaoyi Wang, CEO of BRAINAU. BRAINAU is a leading enterprise in China's cognitive digital therapeutics space Since its establishment in 2012, BRAINAU has been deeply rooted in the field of digital therapeutics, pioneering and leading the way in China's digital therapeutics landscape. By integrating neuroscience with artificial intelligence technology, the company develops medical digital products for cognitive impairment, with its product pipeline covering the assessment and intervention of a wide range of cognitive disorders induced by vascular diseases, neurodegenerative diseases, mental illnesses, and developmental defects in children. Its flagship product, the Brain Function Information Management Platform Software – 66nao, was the first approved cognitive therapeutics products nationwide. Advantages of 66nao Digital Therapeutics: Enhancing Treatment Outcomes for Cognitive Impairment Patients 66nao, a digital therapeutics product under BRAINAU, assists doctors in clinical diagnosis, treatment, outcome assessment, cognitive-linguistic-psychological screening and evaluation, as well as comprehensive management of medical information related to brain function data for patients with brain dysfunction caused by various brain injuries, including cognitive, speech, and psychological impairments. Significant improvements can be observed in neurophysiological data such as neural fiber connectivity, EEG signals, and neurotransmitter density, as well as in clinical assessment scores, after approximately one month of training. Patients also report subjective improvements in memory and other cognitive functions. In 2020, the scope of 66nao's medical device registration certificate was expanded to cover eight indications: vascular cognitive impairment, Alzheimer's disease, aphasia, depression, schizophrenia, sleep disorders, attention deficit hyperactivity disorder, and autism. Advocating the "Neuroscience + AI" Development Strategy to Build a Cognitive Impairment Digital Therapeutics Network BRAINAU continues to advance its research and development of digital therapeutics for cognitive impairment. In 2023, it launched a new product, "Aurora Island of the Mind." Based on evidence-based medicine, Aurora Island of the Mind offers AI-personalized cognitive training through a game-based interactive mode to treat patients with depression. Focusing on the diagnosis and treatment of cognitive impairment, BRAINAU has developed multiple digital therapeutics products, including software for basic cognitive ability assessment, supplementary cognitive ability screening and evaluation, and cognitive impairment treatment. With 21 products in development, BRAINAU aims to provide personalized digital treatments for patients with cognitive impairment induced by conditions such as atrial fibrillation, hypertension, coronary heart disease, and Parkinson's disease in the future. About Frost & Sullivan's Global Leadership Award The Frost & Sullivan Global Leadership Award recognizes enterprises' outstanding performance and exceptional achievements in areas such as technology innovation, market potential, customer service, branding, and others. The Frost & Sullivan team nominated a group of competitive and excellent enterprises through methods including in-depth interviews, industry analysis, and secondary research. An independent judging panel, made up of third-party investment and financing experts, financial experts, bankers, and renowned listed company entrepreneurs, conducted rigorous evaluations of the nominated enterprises and decided to grant 2024 Global Cognitive Impairment Digital Therapy Innovation Award to BRAINAU.
New technologies will contribute to performing genetic tests to diagnose cancers, rare diseases and other diseases with greater precision, advancing personalized medicine in the country SÃO PAULO, Brazil, Sept. 19, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has just formed a strategic alliance with Dasa, the largest medical diagnostics company in Latin America, to expand Brazilian patients' access to next-generation genomics and promote significant advancements in Brazil's healthcare sector. MGI operates in 100 countries and has been active in Latin America since 2019. In April of this year, MGI inaugurated the Customer Experience Center (CEC) in Brazil to strengthen genomic sequencing infrastructure and scientific development in the country. The company's technology also supports Brazil's largest genomic sequencing project, Genomas Brasil. "We are excited to leverage MGI's technology and Dasa's expertise in the diagnostics sector and extensive healthcare network. We will help enhance Dasa's ability to serve an increasing number of patients by processing high-quality genetic samples that are more accessible and efficient," Carlos Carpio, MGI's Senior Commercial Director for Latin America and General Manager for Brazil, says. "With Dasa, we will contribute to strengthening genomics in the country, advancing personalized medicine and promoting health for the Brazilian population", he adds. For Gustavo Riedel, Director of Genomics LATAM at Dasa, the alliance is a crucial advancement for health in the country. "Our expertise in specialized health services combined with MGI's sequencing technologies will ensure greater access for Brazilian patients to precision genomics and, consequently, help in defining more accurate and effective treatments for illnesses such as cancers and rare diseases", the executive explains. In addition to the established alliance, Dasa has implemented MGI's sequencers and automation products in its network of laboratories. The installation of high-throughput DNBSEQ-T7, Automated Sample Preparation System MGISP-100, Automated Sample Preparation System MGISP-960 and ZTRON Appliance equipment will optimize the time of professionals in processing procedures, reducing overall costs and significantly increases the efficiency of the laboratories. The strategic alliance between MGI and Dasa is poised to transform the Brazilian healthcare market by introducing state-of-the-art genomic sequencing technologies. In a country where access to advanced medical technologies has often been limited by high costs, this partnership represents a major step forward. Enabling Brazilian's access to genomic testing, more Brazilians can benefit from the latest advancements in precision medicine. "With the new platform, we have gained a lot in quality, timeliness, productivity, standardization of routine processes and data processing. We want to guarantee more access for the population, in the shortest possible time, at an increasingly affordable cost," explains Riedel. About MGI MGI Tech Co. Ltd. (MGI), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation. MGI's mission is to develop and promote advanced life science tools for future healthcare. For more information, please visit the MGI website or connect on Twitter, LinkedIn or YouTube. About Dasa Dasa is the largest integrated healthcare network in Brazil, touching the lives of over 23 million people per year with cutting-edge technology, intuitive experiences, and a forward-thinking approach. With over 50,000 employees and 250,000 partner physicians, Dasa is committed to providing the healthcare that people want and the world needs, being present at every stage of care. Dasa believes that comprehensive care is essential, which is why it takes a preventive, predictive, and personalized approach to healthcare management. It integrates diagnostic medicine, hospitals, genomics, oncology, care coordination, emergency care, telemedicine, clinical research, and science. In total, Dasa has 15 reference hospitals (including its own network, inorganic growth, and deals still under approval by regulatory agencies), and over 59 diagnostic medicine and hospital brands distributed across hundreds of units in Brazil. Dasa ensures a fast, straightforward, and frictionless healthcare journey for both patients and doctors through its digital healthcare management platform, Nav. Additionally, it offers integrated and innovative corporate health solutions through Dasa Empresas. We are Dasa, and we are here for life. For more information, please visit: www.dasa.com.br
A12 藝術空間
Medical Equipment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
